Vor Biopharma Inc. - VOR
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| May 15, 2026 | SCHEDULE 13G/A | Venrock Healthcare Capital Partners III, L.P. | 9.9% | 5,083,877 | View |
| May 15, 2026 | SCHEDULE 13G/A | VHCP Co-Investment Holdings III, LLC | 9.9% | 5,083,877 | View |
| May 15, 2026 | SCHEDULE 13G/A | Venrock Healthcare Capital Partners EG, L.P. | 9.9% | 5,083,877 | View |
| May 15, 2026 | SCHEDULE 13G/A | VHCP Management III, LLC | 9.9% | 5,083,877 | View |
| May 15, 2026 | SCHEDULE 13G/A | VHCP Management EG, LLC | 9.9% | 5,083,877 | View |
| May 15, 2026 | SCHEDULE 13G/A | Nimish Shah | 9.9% | 5,083,877 | View |
| May 15, 2026 | SCHEDULE 13G/A | Bong Y. Koh | 9.9% | 5,083,877 | View |
| May 15, 2026 | SCHEDULE 13G/A | Verve Capital Limited | 9.3% | 4,999,272 | View |
| May 06, 2026 | SCHEDULE 13G/A | Qiming Venture Partners VIII-HC, L.P. | 2.0% | 1,089,767 | View |
| May 06, 2026 | SCHEDULE 13G/A | Qiming Venture Partners VIII Investments, LLC | 1.7% | 910,172 | View |
| May 06, 2026 | SCHEDULE 13G/A | Qiming GP VIII, LLC | 1.7% | 910,172 | View |
| May 06, 2026 | SCHEDULE 13G/A | Qiming GP VIII-HC, LLC | 2.0% | 1,089,767 | View |
| May 06, 2026 | SCHEDULE 13G/A | FMR LLC | 3.2% | 1,539,670 | View |
| May 06, 2026 | SCHEDULE 13G/A | Abigail P. Johnson | 3.2% | 1,539,670 | View |
| Apr 21, 2026 | SCHEDULE 13D/A | — | 19.9% | — | View |
| Apr 15, 2026 | SCHEDULE 13D/A | — | 19.9% | — | View |
| Apr 10, 2026 | SCHEDULE 13D/A | — | 19.9% | — | View |
| Apr 08, 2026 | SCHEDULE 13D/A | — | 19.9% | — | View |
| Apr 01, 2026 | SCHEDULE 13G | TCG Crossover GP II, LLC | 5.2% | 2,836,539 | View |
| Apr 01, 2026 | SCHEDULE 13G | TCG Crossover Fund II, L.P. | 5.2% | 2,836,539 | View |
| Apr 01, 2026 | SCHEDULE 13G | TCG Crossover GP III, LLC | 5.2% | 2,836,539 | View |
| Apr 01, 2026 | SCHEDULE 13G | TCG Crossover Fund III, L.P. | 5.2% | 2,836,539 | View |
| Apr 01, 2026 | SCHEDULE 13G | Chen Yu | 10.5% | 5,673,078 | View |
| Apr 01, 2026 | SCHEDULE 13D/A | — | 19.9% | — | View |
| Mar 16, 2026 | SCHEDULE 13D/A | — | 9.99% | — | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Great Point Partners, LLC | 3.3% | 1,370,107 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Dr. Jeffrey R. Jay, M.D. | 3.3% | 1,370,107 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Ms. Lillian Nordahl | 3.3% | 1,370,107 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Venrock Healthcare Capital Partners III, L.P. | 9.9% | 2,216,075 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | VHCP Co-Investment Holdings III, LLC | 9.9% | 2,216,075 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Venrock Healthcare Capital Partners EG, L.P. | 9.9% | 2,216,075 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | VHCP Management III, LLC | 9.9% | 2,216,075 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | VHCP Management EG, LLC | 9.9% | 2,216,075 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Nimish Shah | 9.9% | 2,216,075 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Bong Y. Koh | 9.9% | 2,216,075 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Verve Capital Limited | 9.9% | 4,297,464 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Paradigm BioCapital Advisors LP | 4.5% | 1,750,000 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Paradigm BioCapital Advisors GP LLC | 4.5% | 1,750,000 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Senai Asefaw, M.D. | 4.5% | 1,750,000 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Paradigm BioCapital International Fund Ltd. | 4.0% | 1,546,061 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | Qiming Venture Partners VIII-HC, L.P. | 2.8% | 1,089,767 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | Qiming Venture Partners VIII Investments, LLC | 2.4% | 910,172 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | Qiming GP VIII, LLC | 2.4% | 910,172 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | Qiming GP VIII-HC, LLC | 2.8% | 1,089,767 | View |
| Feb 05, 2026 | SCHEDULE 13G/A | FMR LLC | 6.5% | 2,526,170 | View |
| Feb 05, 2026 | SCHEDULE 13G/A | Abigail P. Johnson | 6.5% | 2,526,170 | View |
| Dec 23, 2025 | SCHEDULE 13D | — | 9.99% | — | View |
| Dec 19, 2025 | SCHEDULE 13G | Frazier Life Sciences Public Fund, L.P. | 5.8% | 2,258,001 | View |
| Dec 19, 2025 | SCHEDULE 13G | FHMLSP, L.P. | 5.8% | 2,258,001 | View |
| Dec 19, 2025 | SCHEDULE 13G | FHMLSP, L.L.C. | 5.8% | 2,258,001 | View |
| Dec 19, 2025 | SCHEDULE 13G | Frazier Life Sciences XI, L.P. | 0.1% | 21,114 | View |
| Dec 19, 2025 | SCHEDULE 13G | FHMLS XI, L.P. | 0.1% | 21,114 | View |
| Dec 19, 2025 | SCHEDULE 13G | FHMLS XI, L.L.C. | 0.1% | 21,114 | View |
| Dec 19, 2025 | SCHEDULE 13G | Frazier Life Sciences XII, L.P. | 0.7% | 264,824 | View |
| Dec 19, 2025 | SCHEDULE 13G | FHMLS XII, L.P. | 0.7% | 264,824 | View |
| Dec 19, 2025 | SCHEDULE 13G | FHMLS XII, L.L.C. | 0.7% | 264,824 | View |
| Dec 18, 2025 | SCHEDULE 13D/A | — | 9.99% | — | View |
| Dec 17, 2025 | SCHEDULE 13G | Great Point Partners, LLC | 5.63% | 1,234,486 | View |
| Dec 17, 2025 | SCHEDULE 13G | Dr. Jeffrey R. Jay, M.D. | 5.63% | 1,234,486 | View |
| Dec 17, 2025 | SCHEDULE 13G | Ms. Lillian Nordahl | 5.63% | 1,234,486 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.